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Pain management options for the equine orthopedic patient are limited and can 
have harmful systemic effects. Methods of local drug delivery such as intravenous 
regional limb perfusion (IVRLP) are able to provide more focal therapy with a decreased 
risk of systemic side effects. 
The primary goal of the present study was to develop a novel, targeted pain 
management approach able to mitigate the complications encountered with systemic 
opioid administration. There were two main objectives with respect to elucidating the 
usefulness of a butorphanol IVRLP. The first of these was to evaluate the feasibility of 
IVRLP to deliver butorphanol to the treated limb, and the second was to develop a 
method for evaluating the analgesic efficacy of the procedure.  
The findings suggest butorphanol IVRLP is well tolerated, results in measurable 
levels of butorphanol in the treated limb and may be of analgesic benefit. 
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Pain Management in the Horse 
Pain management options for the equine patient are limited, and investigations 
into novel analgesic protocols have made little progress in comparison to the advances 
made in small animal medicine.1,2 Equine patients, particularly those with painful 
orthopedic conditions, are at risk of a number of sequelae, not only directly due to the 
effects of the drugs used, but also due to the somewhat modest improvements in comfort-
level that are often achieved.1 In addition to the concerns regarding patient welfare, 
persistent discomfort results in a depressed patient with a slower rate of healing and a 
propensity for catastrophic outcomes such as support-limb laminitis.1 As such, it is 
imperative to keep striving for improvement in this area of case management. 
Most commonly, painful conditions in horses are treated with systemic non-
steroidal anti-inflammatory drugs (NSAID) such as flunixin meglumine, phenylbutazone, 
firocoxib and ketoprofen.1–3 These drugs work by inhibiting the cyclooxygenase (COX) 
pathway of the inflammatory cascade and are thus most appropriate in cases where pain 
is secondary to an inflammatory process.1 While considered generally efficacious, 
NSAID therapy is not without consequence.1 Inhibition of the COX pathway inhibits 
production of prostaglandin F2α, a potent inflammatory mediator.1 However, COX 
inhibition can also reduce the production of other, protective prostaglandins in the 
gastrointestinal and urinary tracts.1,4 As a result, consequences of their use include 
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gastrointestinal ulceration and necrosis and renal papillary necrosis – sequelae that can 
become life-threatening.1,4 Development of more selective NSAID has led to improved 
safety profiles for these medications compared to the more traditional, non-selective 
varieties.5 However, while generally considered the “safe” NSAID, more selective drugs, 
such as firocoxib, have also been shown to have similar complications when used for 
prolonged periods or in combination with non-selective inhibitors.6,7 
 Another class of analgesics commonly used in both human and veterinary patients 
is the opioids.8 Opioids work by binding to opioid receptors, of which there are three 
main types – mu, kappa and delta – present both in the central nervous system and 
peripheral tissues.9–15 They have both analgesic and anti-inflammatory effects in horses, 
making them an attractive option for the alleviation of several causes of pain.9–12 
Furthermore, certain opioid receptors have been found to be upregulated in inflamed 
synovium, making opioid drugs with an affinity for these receptors an excellent choice 
for orthopedic pain arising from synovial insult.14 Additionally, a further benefit of 
opioids is that they can be administered via a constant-rate infusion (CRI), providing 
continuous, regulated doses that result in consistent pain management.10,16 Despite these 
benefits, systemic use of opioids in horses is associated with significant disadvantages.8 
When used alone, opioids are reported to cause dangerous and unpredictable central 
nervous system excitation, although this is uncommonly seen in the clinically painful 
patient.10 A more commonly cited reason for avoiding opioid use in equine patients is the 
resulting reduction in gastrointestinal motility that is considered to put the patient at an 
increased risk for colic.8–11 The negative gastrointestinal effects of opioids have been 
predominantly attributed to mu receptor agonism, such as with morphine, a pure mu 
agonist.9,11,17,18 Butorphanol, by comparison, is an opioid that is typically more readily 
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available and widely used in equine practice.2,19 Its analgesic effects following systemic 
administration in adults have been well studied, and it is also an effective, well-tolerated 
option for young foals.2,11,21–31 Butorphanol is unique in that is it is considered an opioid 
agonist-antagonist, having predominant activity at kappa receptors and some degree of 
mu receptor antagonism.16,17,21 Its reduced mu activity is thought to explain the less 
significant impact it has on gastrointestinal motility in comparison to other opioids such 
as morphine.16,17,21 Additionally, the kappa agonism has been thought to offer a further 
advantage, as kappa agonist use has been shown to be of benefit in human and animal 
joint disease models.30,31  
Given the problems associated with NSAID and systemic opioid use, other drug 
classes have been investigated for their analgesic benefits, including alpha-2 adrenergic 
agonists, local anesthetic agents, dissociative anesthetics, or some combination of 
these.2,4,32,33 Alpha-2 agonists, such as xylazine and detomidine, provide potent analgesia 
in addition to their sedative effects, but are not always an appropriate choice given the 
sedation and ataxia they induce.34 Lidocaine is a commonly utilized local anesthetic agent 
that, when delivered as a CRI, can provide both analgesic and anti-inflammatory 
benefits.2 However, its administration requires maintenance of a patent catheter, as well 
as close monitoring to avoid overdose which may result in ataxia or sudden collapse – 
neither of which is desirable, particularly in the case of an orthopedic patient.2,33 Lastly, 
ketamine, a dissociative anesthetic, has been utilized at sub-anesthetic doses either alone 
or in combination with one or more of the aforementioned drug classes to provide 
analgesia.32 Uncommonly used on its own due to its short duration of action, its use in 
combination with opioids, local anesthetics or alpha-2 agonists (i.e. such as in a tri- or 
penta-fusion CRI) has been reported to provide significant pain relief.6,32 However, this is 
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associated with the sequelae of the other medications with which it is administered – such 
as delayed gastrointestinal motility, ataxia, etc. – and thus also not an ideal choice for 
many cases. Other analgesic options available for use in horses include gabapentin, 
tramadol and paracetamol, however, their use is much less frequent and less well 
described in the literature so will not be discussed in any further depth here.2,35 
Due to the clear downsides of these systemically-administered options, alternate 
routes of analgesic drug delivery have been investigated. These include direct delivery 
via soaker catheters or intra-articular injection, use of transdermal patches, or epidural 
administration in either a bolus dose or via an indwelling catheter.1,2,35,36 The benefit of 
these local therapies is the elimination or reduction of the sequelae seen with systemic 
administration. However, each of these brings its own set of shortcomings: soaker 
catheters are of limited use due to an inability to maintain patency and the quantity of 
drug needed; intra-articular injection requires repeated puncture of the synovial 
environment, risking synovial flare or sepsis; transdermal patches are variably efficacious 
and often not cost effective; and epidural catheters are only of benefit for hindlimb 
conditions, must be meticulously managed, and carry a risk of ascending infection.1,2,35–39 
More recently, investigation into the use of local limb perfusions as a route of analgesic 
drug administration has garnered interest.40,41 This route involves administration of a 
small volume of drug to a particular region of the body that is isolated by way of a 
tourniquet.42 To date, the predominant choice for such perfusions has been local 
anesthetics, however there has been recent interest in utilizing this approach to administer 
other analgesics, such as opioids.40–42 
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Regional Limb Perfusion 
 Due to concerns regarding the efficacy, safety and cost associated with systemic 
medication administration to horses, several routes of local drug delivery have been 
developed.43 These routes include direct intra-synovial or intra-thecal injection, 
impregnated materials placed into the site of interest, or local perfusions via the 
vasculature or medullary cavities in the vicinity.43,44 Of these, intravenous regional limb 
perfusion (IVRLP) is perhaps the most common method utilized in horses.42,44,45 
 IVRLP is a method by which a drug solution, known as the perfusate, is 
administered into a local area that is isolated from the rest of the body by some form of 
tourniquet.44 In horses the technique is restricted to use in the distal extremities, as these 
are the only regions that can be isolated by tourniquet application.43 Once the tourniquet 
is placed, a prominent vessel distal to the tourniquet is used to administer the perfusate to 
the region.44 The technique relies on both concentration and pressure gradients, created 
by a highly concentrated perfusate and the increased intravascular pressure created by the 
tourniquet, to force diffusion of the drug into surrounding tissues.44 The primary benefit 
of this route of administration is the ability to use far lower doses than would be needed 
to achieve an equivalent concentration in the area if the drug were to be given 
systemically.42 Often, drug concentrations that can be reached via IVRLP would be 
impossible or unsafe to achieve with systemic administration.46,47 In addition to this 
improved safety profile, an important secondary benefit is the reduced cost associated 
with the lower doses used, and generally shortened duration of therapy required.42,44 
 To date, IVRLP in horses has predominantly been used to deliver high 
concentrations of antimicrobials to the distal limbs of horses to treat a variety of 
conditions, such as synovial sepsis and contaminated wounds, as well as for prophylactic 
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perioperative antibiotic delivery.42 Antimicrobial IVRLP has been shown to result in 
concentrations in the target tissues far exceeding the necessary minimum inhibitory 
concentrations needed for a variety of agents.43 This application has unquestionably 
improved the outcome of many complicated cases, by speeding recovery, reducing the 
risk of sequelae, and drastically reducing the cost of treatment.43,44 However, this 
technique is not limited to antimicrobial delivery.40,41,44,46,48,49 It has also been utilized to 
deliver anti-inflammatory, anesthetic and analgesic agents in an attempt to augment 
traditional pain management protocols.7,12,13 Although infrequently reported in equine 
patients, the administration of local anesthetic agents via IVRLP is routine in both bovine 
and human medicine.40,44,50 IVRLP with dimethyl sulfoxide has also been used 
successfully for anti-inflammatory therapy of septic distal limb conditions in horses, and 
recently interest has developed in utilizing this route of administration for opioid 
delivery.41,48 
The use of IVRLP for equine analgesia is an attractive concept, as this could offer 
a means by which to provide targeted pain relief, while simultaneously avoiding the 
complications associated with systemic analgesic administration. In particular, opioids 
seem to be ideal candidates for IVRLP, given the need to avoid their significant systemic 
side effects. Additionally, they cause neither the perivascular irritation reported with 
NSAID administration, nor the complete desensitization that occurs with local 
anesthetics. Hunter et al. (2015) were the first to investigate opioid IVRLP in horses. 
They evaluated this route of administration for morphine, a pure mu opioid receptor 
agonist, as it had previously been reported that mu receptors are upregulated in 
osteoarthritic equine joints.14,41 They were able to show that morphine IVRLP in the 
forelimbs of horses resulted in measurable levels in the synovial fluid of the middle 
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carpal joint, although the clinical benefit this provided was not investigated.41 However, 
morphine has been reported to cause a profound decrease in motility in several species, 
which has been attributed to its pure mu activity.9,11,17,18 In comparison, butorphanol has 
been associated with less severe sequelae and may thus offer a good alternative for opioid 
IVRLP.17 Its reduced mu activity is thought to explain its lesser impact on gastrointestinal 
motility.16,17,21 This antagonist activity at mu receptors also suggests the benefits of 
butorphanol use must stem from a mechanism different than those proposed for 
morphine. While the kappa receptor distribution and effects are not as well understood in 
horses, peripheral kappa receptors have been identified and kappa agonists have been 
shown to be of benefit in joint disease models in other species.30,31,51 Specifically, local 
kappa agonist use reduces intra-articular inflammation in rats, and in human arthritis 
patients has demonstrated anti-arthritic effects and stimulated upregulation of kappa 
receptors, suggesting a beneficial positive feedback effect.30,31 The present study aimed to 
elucidate the usefulness of butorphanol for IVRLP. If effective, this would offer the 
equine practitioner an additional tool for multimodal analgesia in patients suffering from 
painful distal limb conditions. 
Antinociceptive Testing 
When investigating the use of a novel analgesic IVRLP, there must be a means by 
which to objectively assess the pain modulation it provides. This presents a challenge, 
however, as testing analgesic efficacy can be difficult in horses, due to their temperament 
and potentially violent responses to pain.26 In clinical cases where the patient displays 
clear signs of discomfort, it may be relatively easy to identify an improvement in their 
clinical picture, and objective scoring systems such as the equine pain scoring system, 
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lameness scales or a lameness locator can be used.52,53 However, identifying an effect in a 
healthy, non-painful subject, such as those used in drug studies, may be more difficult. 
The most commonly reported method of assessing pain and responses to analgesia 
in animals is nociceptive testing, also known as analgesiometry.26,54 It involves the 
application of a quantifiable noxious stimulus until a behavioral or physiological 
avoidance response is elicited, at which point application of the stimulus is 
terminated.26,53 The point at which the animal shows an avoidance response is termed the 
animal’s nociceptive threshold.26,55 For safety reasons, a pre-set end-point is determined 
prior to testing, beyond which the animal is considered to have no response and no 
further stimulus is applied.26 Several things can influence nociceptive thresholds, 
including analgesic administration or abnormal physiological responses to pain such as 
hyperalgesia (increase in response to pain and thus decreased thresholds) due to 
sensitization or hypoalgesia (reduction in response to pain and thus increased thresholds) 
due to habituation.26 When assessing the efficacy of a particular analgesic, if the drug is 
effective this should be manifest as an increase in this threshold (i.e. it should require 
more noxious stimulus to achieve a response).26,55 
Several different types of noxious stimuli have been utilized in nociceptive testing 
of horses, including thermal, electrical and mechanical means.26,53 Thermal methods have 
included such things as cutaneous warming via heat lamps or heating via direct contact of 
thermodes with tissues.26,56 Electrical stimulation is usually created via transcutaneous 
electrodes or via implantation of electrodes along a nerve of interest.57,58 Mechanical 
stimuli are generally some form of pressure application, either with a hand-held 
algometer or utilizing a pneumatic cylinder that transmits pressure via an attached blunt 
ended pin.26 Mechanical methods tend to be easier to instrument consistently and have 
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safer end-points than thermal or electrical methods, with fewer significant complications 
(i.e. minor skin bruising versus burns or violent reflex responses).26 A recent study 
reported excellent validity of each of three types of stimuli – citing good sensitivity, 
specificity and reliability.55 However, when ranked with respect to efficacy for testing the 
distal limb, mechanical testing was deemed the most sensitive, followed by thermal and 
electrical.55 It is also argued that mechanical testing is the most appropriate with respect 
to horses, given that most nociceptive stimuli equine patients experience are mechanical 
(e.g. weight bearing, blunt trauma, lacerations, etc.).55 
Nociceptive threshold testing has previously been used to evaluate the efficacy of 
analgesic administration in horses.23,59 It has been shown that thermal and mechanical 
nociceptive thresholds increase in response to systemic administration of butorphanol, 
supporting its use as an analgesic.23,26 Mechanical nociceptive testing has also been used 
to investigate the consequences of adding of a local anesthetic to an antibiotic IVRLP.40 
Addition of mepivacaine hydrochloride to an amikacin IVRLP resulted in increased 
MNT, suggesting an analgesic effect.40 It was also shown that addition of this agent did 
not significantly affect the concentrations of antibiotic achieved, nor its antimicrobial 
efficacy – important considerations if planning to use a combined IVRLP.40 Based on 
these findings, it was expected that mechanical nociceptive testing would be an 






The present study had two objectives with respect to elucidating the usefulness of 
butorphanol IVRLP. The primary objective was to evaluate the feasibility of IVRLP to 
deliver butorphanol to the radiocarpal joint of the treated limb. It was hypothesized that 
cephalic IVRLP with 10 mg of butorphanol would result in measurable concentrations in 
the radiocarpal joint for several hours. The second objective was to develop a method for 
evaluating the analgesic efficacy of the procedure. It was hypothesized that butorphanol 
IVRLP would result in a significant increase in mechanical nociceptive thresholds 
(MNT) in treated limbs versus untreated control limbs, consistent with an analgesic 
effect. 
Animals 
Six healthy adult horses (median weight 480 kg; range 422 - 560) including two 
mares and four geldings (four American Quarter Horses and two Arabians) were used in 
the study. All horses were deemed healthy following physical examination. Each horse 
was deemed sound (grade 0/5) in the forelimbs, according to the American Association of 
Equine Practitioner (AAEP) 5-point lameness scale, and showed no response to bilateral 
carpal flexion.60 No horse had any evidence of superficial skin injury on the limbs, and 
all were confirmed to respond to pressure applied over the dorsal distal limb. No horse 
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received opioids in the two months prior to inclusion in the study. Horses were 
hospitalized 24 hours prior to their respective sampling day and housed in box stalls for a 
total of five days before returning to usual turnout. Procedures were performed with the 
approval of the Institutional Animal Care and Use Committee.  
Intravenous Regional Limb Perfusion and Sample Collection 
The limb to be treated was assigned using a masked random draw. The other 
forelimb was left untreated as a control for MNT testing, as described below. Prior to 
sedation for IVRLP, baseline (T0) blood and synovial samples were collected and 
baseline MNT testing was performed. Prior to IVRLP administration and each sample 
collection, the cephalic vein, jugular veins and dorsal aspect of the carpus were 
aseptically prepared using 4% chlorhexidine gluconate scrub and 70% isopropyl alcohol. 
Blood samples were collected into 10 mL red top (no additive) glass tubes using standard 
vacutainer equipment. Synovial fluid samples (1 mL) were collected from the radiocarpal 
joint using sterile technique and a 20-gauge, 1.5 cm hypodermic needle via a dorsolateral 
approach before being transferred to a 3 mL purple-top (EDTA) glass tube. 
Following collection of the T0 samples, the horses were sedated with detomidine 
hydrochloride (5 mg total or 0.009 - 0.012 mg/kg intravenously [IV]). One 10.6 cm wide, 
30.5 cm long rubber tourniquet (Latex Esmark Bandage; Jorgensen Laboratories, Inc., 
Loveland, CO) was placed as tightly as possible around the radius of the selected limb, 
extending proximally from the level of the chestnut. Two gauze rolls were placed on the 
medial and lateral aspect of the limb under the tourniquet to improve vascular 
compression. IVRLP was then performed using sterile technique with a 23-gauge, 1.91 
cm butterfly catheter with the needle directed distally in the cephalic vein, distal to the 
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tourniquet and proximal to the radiocarpal joint. The perfusate (10 mg butorphanol 
tartrate diluted to a total volume of 30 mL with sterile 0.9% NaCl) was administered by 
hand over three minutes. The needle was removed following infusion and the site was 
covered with a temporary bandage of gauze and inelastic tape for the duration of the 
perfusion. The horse was left to stand with the tourniquet in place for 30 minutes, with 
monitoring of limb movement and supplemental sedation with xylazine boluses (50 - 200 
mg or 0.12 - 0.36 mg/kg IV) administered if excessive movement (i.e. repeated placing or 
walking) was observed. Subtle swaying or shifting in the hind end did not prompt 
additional sedation. All perfusions were video-recorded to allow subsequent movement 
analysis. 
Immediately following tourniquet removal, blood and synovial fluid samples were 
collected, as described above, at 0.5, 1, 2, 4 and 6 hours after conclusion of the IVRLP. 
All time points were in relation to the conclusion of the IVRLP perfusate administration – 
for example, the 0.5-hour sample was taken immediately after tourniquet removal, which 
was 0.5 hours (or 30 minutes) after conclusion of the IVRLP administration. MNT testing 
was also repeated at these intervals, as described below. Between collections, the 
sampled carpus was bandaged with a sterile rolled gauze and elastic bandage to keep the 
area free from contamination. Following the final synoviocentesis, 500 mg of amikacin 
was administered intra-articularly and each horse received a single dose of 
phenylbutazone (4.4 mg/kg IV once). 
Blood and synovial fluid samples were centrifuged at 3500xg for five minutes 
within 30 minutes of collection, and aliquots of each were transferred to 3 mL red top (no 
additive) glass tubes to be subsequently frozen at -80 °C until analysis. The stability of 
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the drug in frozen synovial samples was verified in a separate method validation project 
prior to the study (unpublished data). 
Mechanical Nociceptive Threshold Data Collection 
Prior to IVRLP, baseline MNT measurements were obtained from both treated 
and control limbs. Three stimulation sites were tested: the dorsolateral aspect of the mid-
diaphysis of the third metacarpal bone; the dorsolateral aspect of the mid-diaphysis of the 
proximal phalanx; and the dorsal coronary band. The same handheld pressure algometer 
(FPK 10 Wagner Pain Test Algometer; Wagner Instruments, Greenwich, CT), with a 6.5 
mm diameter flat steel probe with rounded edge and stimulation area of approximately 33 
mm2, was used for all measurements and all were performed by the same investigator. 
The range of the algometer was 0.0 - 5.0 kg/cm2 and the maximum of this range was used 
as the safety end point (i.e. pressure application was discontinued if this reading was 
reached, even if there was no response) in order to avoid tissue damage. Each stimulus 
was performed as a ramped pressure, until the horse expressed the behavioral avoidance 
reaction of removing the leg from the probe, or until the safety end point was reached, 
both of which terminated the stimulus and was recorded as the MNT. Two repeated MNT 
measurements were taken approximately 15 seconds apart and averaged for analysis. 
Horses were blindfolded prior to testing. Pre- and post-sedation measurements were taken 
three minutes before and after administration of sedation, respectively, and prior to 
tourniquet application. The remaining measurements were taken immediately following 
tourniquet removal (0.5 hour following IVRLP) and at 1, 2, 4 and 6 hours following 




The horses were evaluated for attitude and comfort level hourly and received 
physical exams every four hours, including enumeration of manure piles, the day of the 
procedure. These were subsequently performed every four and eight hours, respectively, 
for the four additional days of stall rest. Each horse was also assessed and graded 
according to the AAEP lameness scale by the same investigator once daily, after which 
the injection and synoviocentesis sites were evaluated for swelling. This investigator was 
not blinded to the treated limb; however, they did not review this information prior to the 
assessment and was not aware of the MNT or butorphanol analysis results. Once returned 
to pasture, the horses were evaluated for attitude and comfort once daily for an additional 
week. 
Sample Analysis 
Butorphanol was extracted from serum and synovial fluid samples by a solid-
phase extraction (SPE) procedure. Samples were first prepared for analysis by vortexing 
with acetonitrile for protein precipitation. Waters Oasis® HLB cartridges were 
conditioned with approximately 5 mL of optima grade methanol, followed by 
approximately 5 mL of optima grade water. Samples were then passed through the 
cartridges at approximately 0.5 mL/min. The SPE cartridge was washed with 5 mL of 
optima grade water and allowed to dry for 10 minutes under vacuum. The butorphanol 
was then eluted from the cartridge with 4 mL of methanol containing 2% formic acid. 
Once the samples were eluted from the SPE cartridge, they were evaporated under 
nitrogen gas in a 55°C water bath. The samples were reconstituted to 2 mL with optima 




Chromatographic separation was performed using an Agilent 1260 Infinity High 
Performance Liquid Chromatograph equipped with an Agilent Xorbax Eclipse Plus C18 
(2.1 x 50 mm) 1.8 µm analytical column at 40°C for respectable peak resolution. Optima 
grade water and methanol with the addition of 0.1% formic acid and 5 mM ammonium 
formate were used as mobile phases with a 5 µL injection volume. The HPLC was 
coupled to an Agilent 6360 Triple Quadrupole Mass Spectrometer. The samples were 
analyzed using positive electrospray ionization. The following mass spectrometer 
conditions were used: sheath gas temperature, 300°C; drying gas temperature, 350°C; 
sheath gas flow, 11 L/min; nebulizer pressure, 40 psi; and capillary voltage, 4000 volts. 
Multiple reaction monitoring transitions included 328.2 to 310.2 for quantitation, and 
328.2 to 157.0 and 328.2 to 56.1 for qualitative purposes. Data collected from the LC-
MS/MS was assessed using MassHunter B.04 software from Agilent. Based on the 
aforementioned method validation study, the limits of detection and quantification for the 
described method were 0.05 ng/mL and 0.15 ng/mL, respectively. 
Statistical Analysis 
Initially, linear mixed models were used to assess the effect of time on 
concentration of butorphanol in synovial fluid and serum. However, the models did not 
meet the assumptions of normality and homoscedasticity. Consequently, a method similar 
to the non-parametric Friedman’s test was used. Synovial and serum values were first 
ranked using PROC RANK in SAS for Windows 9.4 (SAS Institute, Inc., Cary, NC) and 
then analyzed by linear models using PROC MIXED in SAS for Windows 9.4. Time and 
horse identity were the fixed effects.  
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The effect of site, treatment, and time on pain MNT was assessed by linear mixed 
models using PROC MIXED in SAS for Windows 9.4. The initial model included site, 
treatment, time and all two-way interactions. Horse was included as a random effect to 
address the measure of pain threshold at multiple sites in each horse. To address the 
repeated measures over time, horse by treatment by site was the subject of a repeated 
statement with a spatial power covariance structure. If after fitting the model an 
interaction term was not significant, it was removed. This was repeated until only fixed 
effects and significant interaction terms remained in the model. Using a similar model, 
but replacing treatment with synovial concentrations of butorphanol, mixed model linear 
regression was used to assess the association of pain threshold and synovial 
concentrations of butorphanol in treated horses. As above, horse was included as a 
random effect and horse by site was the subject of a repeated statement with a spatial 
power covariance structure.   
In the case of a significant fixed effect in the models, differences in least squares 
means among variable levels were accessed using the SIMULATE option to adjust p-
values for multiple comparisons. The distribution of residuals was evaluated to assess if 
the assumptions of normality and homoscedasticity had been met for all models. An 
alpha level of 0.05 was used to determine statistical significance. 
To assess the degree of variation between the two measurements of MNT made at each 
assessment, the coefficient of variation using the logarithmic method was calculated.61,62 
Briefly, the data were first log transformed. For each measurement pair, the square root 
of the mean within-pair variance was calculated to provide the within-pair standard 
deviation. The coefficient of variation was then calculated by taking the antilog of the 





IVRLP and MNT procedures were well tolerated by all horses. IVRLP was 
successful in 5/6 horses, yielding detectable levels of butorphanol in synovial fluid 
(Figure 1A). In one horse, no butorphanol was detected in the radiocarpal joint of the 
treated limb at any time point, and no systemic levels were detected until two hours post-
perfusion (T2). As such, data from this horse were excluded from further analysis.  
Butorphanol Concentrations 
Butorphanol was not detected in any baseline (T0) synovial fluid samples. 
Measurable concentrations of butorphanol were achieved in the radiocarpal joint of all 
horses, with the exception of the aforementioned exclusion. In 4/5 horses with detectable 
levels, the concentration was highest in the sample collected 30 minutes after perfusion 
(T0.5) and subsequently decreased at each additional sampling. In one of the five horses, 
the highest concentration was measured at one hour (T1) post-perfusion and subsequently 
declined. Synovial concentrations remained significantly above baseline until the four-
hour time point (T4) (p ≤ 0.017), at which point the differences were no longer 
significant (p ≥ 0.767). The overall mean peak synovial butorphanol concentration was 
9.47 ng/mL ± 12.00 ng/mL SD. Butorphanol was no longer detectable by two hours post-
perfusion in 2/5 horses, by four hours in two of the remaining three horses and by six 
hours in the last horse. 
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No butorphanol was measured in any serum samples collected prior to IVRLP. 
Butorphanol was detectable in the serum of 4/5 horses at 30 minutes post-perfusion 
(T0.5), and 5/5 horses by one-hour post-perfusion (T1) (Figure 1B). Serum 
concentrations remained significantly above baseline until the two-hour time point (T2) 
(p ≤ 0.016), at which point the differences were no longer significant (p ≥ 0.518). The 
overall mean peak serum butorphanol concentration was 3.89 ng/mL ± 3.29 ng/mL SD. 
Butorphanol was no longer detectable in the serum of any horse by six hours post-
perfusion. 
Mechanical Nociceptive Threshold Testing 
Mean MNT values are provided in Table 1. MNT values were not significantly 
different among the three testing sites (p = 0.955); however, there was a significant time 
by treatment interaction (p = 0.022). No significant differences were detected between 
control and treated limbs prior to IVRLP (p = 0.999). No significant differences (p > 
0.944) were found between treated and control limbs following IVRLP, with the 
exception of one-hour post perfusion (T1), at which point the MNT of the control limbs 
were higher than that of treated limbs (p = 0.047) (Figure 2). The coefficient of 
variability for these repeated measures was 0.18. 
When evaluated with a linear regression model accounting for the effect of time, a 
positive association between synovial butorphanol concentration and MNT was found (p 
= 0.003). More specifically, for each 1 ng/mL increase in synovial concentration there 





Clinical Examination and Complications 
All vital parameters remained within normal limits throughout the hospitalization period. 
Gastrointestinal borborygmi and manure output remained regular and consistent for all 
horses throughout the period of hospitalization. No signs of gastrointestinal pain or 
inappetence were observed. All horses remained sound in the forelimbs (grade 0/5 on the 
AAEP lameness scale) for the duration of the hospitalization period. Two horses 
developed mild swelling of the perfusion site and two developed mild swelling over the 
synoviocentesis sites in the first two days following perfusion but remained sound and 
improved with hydrotherapy and wrapping prior to turnout. No lameness or swelling was 
















Table 1 Mean ± SD MNTs (in kg/cm2) in control limbs vs. limbs treated with 
butorphanol IVRLP in the five horses with measurable synovial butorphanol 
concentrations following IVRLP. 
  
Third Metacarpal  Proximal Phalanx Coronary Band 
Time Treated Control Treated Control Treated Control 
T0 3.09 ± 1.15 2.86 ± 1.71 3.39 ± 1.16 3.02 ± 1.70 3.11 ± 1.14 2.87 ± 1.68 
T0.5 4.61 ± 0.73 4.13 ± 1.29 4.25 ± 1.68 4.06 ± 1.34 4.56 ± 1.00 3.80 ± 1.35 
T1 3.01 ± 0.91 3.91 ± 1.21 3.09 ± 1.89 4.09 ± 0.86 2.95 ± 1.39 4.39 ± 0.84 
T2 3.48 ± 2.08 3.94 ± 1.49 3.15 ± 1.75 3.58 ± 1.88 3.44 ± 1.80 3.61 ± 1.54 
T4 2.68 ± 0.82 3.29 ± 1.29 2.70 ± 1.43 3.06 ± 1.32 2.49 ± 1.00 2.99 ± 1.35 
T6 2.82 ± 1.61 3.56 ± 1.53 2.40 ± 1.73 3.36 ± 1.61 2.75 ± 1.52 3.20 ± 1.73 
Testing performed at: the dorsolateral aspect of the mid-diaphysis of the third metacarpal 








Figure 1. Radiocarpal synovial fluid butorphanol concentration following butorphanol IVRLP in six healthy, standing sedated 
horses. 
A. Radiocarpal synovial fluid butorphanol concentrations. B. Serum butorphanol concentrations. Synovial concentrations for 






Figure 2. Mean mechanical nociceptive thresholds (MNTs) in limbs treated with butorphanol IVRLP versus untreated control 
limbs. 
Means shown are of the 5 horses in which IVRLP was successful. A. Mean MNT at the level of the third metacarpal (MC3). B. 






Cephalic IVRLP resulted in quantifiable concentrations of butorphanol within the 
synovial fluid of the radiocarpal joint. Furthermore, synovial butorphanol concentrations 
were positively associated with an increased MNT. All horses included in the analysis 
achieved measurable synovial butorphanol levels within 30 minutes following perfusion 
and levels remained measurable for two to four hours.  
The duration of measurable synovial butorphanol concentrations observed in the 
present study is consistent with expectations based on the short plasma half-life reported 
following intravenous and subcutaneous administration of the drug.21 This duration is 
also similar to that of synovial morphine concentrations reported following morphine 
IVRLP.41 While it could be argued that this short duration limits the use of this modality 
for ongoing pain management, an interesting consideration would be what concentrations 
may be achieved in the surrounding soft tissues following IVRLP. The half-life of 
butorphanol following subcutaneous administration has been reported to be longer than 
that following intravenous administration.21 Given the degree of extravascular diffusion 
that occurs with IVRLP, it is expected that the subcutaneous tissues may act as an 
effective depot site and maintain sustained butorphanol concentrations in the treated 
region.63 This may impart an additional benefit of IVRLP over systemic or intra-articular 
use in cases of distal limb surgery or injury, which is likely to be underestimated by 
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studies limited to sampling synovial fluid only. Further investigation of the 
concentrations achieved in the soft tissues of the distal limb following butorphanol 
IVRLP is warranted. 
The synovial fluid concentrations achieved in the present study were highly 
variable, and it is unknown whether the concentrations achieved would be clinically 
relevant. This variability is a common finding in IVRLP studies.63,64 It has been 
speculated that this occurs due to inherent anatomical or physiological differences 
between horses, varying efficacy of the procedure, or sample collection issues.64 Perhaps 
the most commonly cited reason for variability is poor tourniquet efficacy.64,65 Based on 
the fact that four horses had serum butorphanol levels at the time of tourniquet removal 
(T0.5), it is considered likely that leakage under the tourniquet occurred and the IVRLP 
technique used could be improved. Very little consensus has been reached regarding the 
specifics of how IVRLPs should be performed, which limits direct comparisons between 
studies and the ability to identify sources of variability. There is continued debate 
concerning the ideal technical aspects of the procedure (e.g. tourniquet type and number, 
perfusate volume, perfusion time, etc.) and, to date, the available data are largely 
equivocal.44,47,63,64,66–69 The IVRLP procedure performed in the present report was 
intended to reproduce that which may be easily performed by the general practitioner and 
attempts were made to ensure consistency of the IVRLP procedure and sample collection 
between horses. It is possible that use of a different methodology may have reduced the 
variability of the results, but the literature suggests variability is likely regardless of the 
procedure used. Knowing this degree of variability is likely, follow-up studies should 
ensure adequate subject numbers.   
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When considering a novel drug for use in IVRLP, an objective method for 
assessing its efficacy is needed. With respect to antimicrobial IVRLP this is relatively 
straightforward and can be achieved by comparing the concentrations reached with 
known minimal inhibitory concentrations or the effect of such levels on microbial 
growth.40,42,44,45,70 With respect to an analgesic IVRLP, however, there is no clear target 
concentration. Previous nociceptive studies have shown intravenous butorphanol 
administration imparts an analgesic benefit when administered at a dose of 0.1 mg/kg (50 
mg in an average 500 kg horse).23,71 A pharmacokinetic study of butorphanol 
administration in horses have shown that a single dose of butorphanol at this dosage 
resulted in plasma concentrations > 100 ng/mL, much higher those achieved within 
synovial fluid in the present study.28 However, when administered as a constant-rate 
infusion, the mean plasma concentration achieved was 29 ng/mL, a concentration similar 
to that seen in the synovial fluid in the present study.28 It is also of note that the same 
study evaluated the severity of gastrointestinal and locomotor side-effects following these 
doses, finding significantly less severe effects in the constant-rate infusion group.28 A 
similar pattern of less severe side-effects was also reported in association with lower 
plasma concentrations achieved following subcutaneous administration versus 
intravenous administration.21 While it is tempting to try to draw conclusions based on 
these studies, how these systemic concentrations compare to those required locally is 
unknown. Nociceptive testing was performed concurrently in the present study, in 
anticipation that this could be used to identify differences in thresholds between treated 
and untreated limbs, as well as a relationship between the concentrations reached and the 
degree of threshold increase. Of the various analgesic testing techniques, mechanical 
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nociceptive testing was chosen as it has been reported to be the most reliable and 
appropriate, the argument being that most nociceptive stimuli that equine patients 
experience are mechanical (e.g. weight bearing, blunt trauma, lacerations, etc.).26,53,55 
Similar MNT testing has been used to evaluate systemically-administered analgesics, 
including butorphanol, as well as the efficacy of a local anesthetic IVRLP.23,40,59 As 
hypothesized, the present study identified a significant positive association between 
synovial butorphanol concentration and MNT, suggesting that both this testing 
methodology and route of administration for distal limb analgesia may have merit. 
However, due to the relatively small sample size, there was insufficient data to make 
meaningful comparisons between treated and control limbs at a particular time point or 
between particular synovial concentrations and MNT changes. Furthermore, the 
necessary use of sedatives for IVRLP further complicated the analysis, given that alpha-2 
agonist sedative drugs have also been shown to alter MNT responses.59 All horses were 
seen to have a dramatic increase in MNT of both treated and untreated control limbs 
following sedation, which likely affected the ability to identify subtle changes in 
nociception between limbs. While sedation inevitably confounds the interpretation of 
results, it is required for safe and effective IVRLP and should have affected both the 
treatment and control limbs to the same degree, rendering comparisons still relevant. 
Additional studies with a larger sample size are necessary to more specifically investigate 
these effects and hopefully identify a specific intra-synovial concentration associated 
with an analgesic effect, thereby providing an appropriate target concentration. 
An interesting finding in the present study was that the only significant difference 
identified between treated and control limbs was the increased MNT in the control limb 
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versus the treated limb at one-hour post-perfusion. This result is counter to what would 
be expected. However, after review of the timing, it is suspected that this represents a 
period of hyperalgesia following tourniquet removal. Tourniquets are known to cause 
discomfort in human patients, such that their use is predominantly restricted to 
anesthetized patients.72–74 Similarly, their use in minimally-sedated horses can result in 
violent responses, necessitating the use of sedation prior to IVRLP.44 Tourniquet release 
is reported to cause pain in human patients, which is also suspected in equine patients 
based on their repetitive limb movements after removal.73 It is possible that, in 
conjunction with small sample size, this unexpected effect on MNTs may have masked 
the analgesic effects expected from the butorphanol IVRLP. The only other study to 
assess MNT changes in horses following use of a tourniquet was the previously cited 
Colbath et al. (2016) IVRLP study, and they did not appreciate this pattern of decreased 
MNTs in the treated limb.40 However, their last MNT testing was performed immediately 
after tourniquet removal which, assuming a similar pattern of response occurred, would 
not have captured this effect, given it was not seen until the tourniquet had been off for 
30 minutes.40 Thus, further research into the effect of tourniquet application and release 
on MNTs in horses is warranted. Additionally, any future analgesic IVRLP investigations 
planning to use similar methodology should also place a tourniquet on the control limb to 
mitigate this potential confounding factor.  
All horses were monitored closely for evidence of significant local or systemic 
side-effects associated with the butorphanol IVRLP. With respect to local effects 
associated with the perfusion itself, some mild swelling was seen at the sampling and 
injection sites for one to two days post-procedure but resolved with conservative 
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management. Such mild local responses are typical for these procedures and considered 
unlikely to be due to the specific use of butorphanol.42 Due to concerns regarding 
gastrointestinal sequelae from opioid use, routine physical exams and quantification of 
manure output were used to subjectively assess for signs of abdominal discomfort or 
slowed gastrointestinal transit. The vital parameters of all horses remained within normal 
limits for the duration of the study period, none exhibited inappetance or signs of 
abdominal discomfort, and manure output remained consistent for each horse throughout 
the study. The addition of a motility marker, such as feeding inert beads, would have 
offered an opportunity to more objectively characterize the rate of passage of manure and 
thus any significant changes in motility. An inherent limitation of the present study, 
however, was the potential for a confounding effect of sedation. Decreased 
gastrointestinal motility following administration of alpha-adrenergic agonist drugs such 
as detomidine is well documented.11,34 As IVRLP necessitates the use of a sedative, the 
additional expense of incorporating some form of rate of passage indicator for the present 
pilot project was deemed unjustified. However, this may be considered for follow-up 
studies, particularly if different opioid IVRLPs are to be compared.  
There are some important considerations regarding clinical utility of this IVRLP 
protocol. It should be noted that the horses used in the study were sedated with only an 
alpha-2 agonist for the IVRLP. As practitioners may routinely use a sedation protocol 
including both an alpha-2 agonist and an opioid, it is advisable to consider the total horse 
dose in these cases. Based on the present study, no comment can be made with respect to 
the systemic effects of both a systemically-administered sedative dose and a local dose 
delivered by IVRLP. A further consideration that requires evaluation prior to clinical use 
 
29 
is whether there is a reduction in either antimicrobial or analgesic efficacy when opioids 
are combined with an antimicrobial for IVRLP. This has been previously evaluated with 
respect to local anesthetics, and the same should be pursued for opioids, as IVRLP offers 
an appealing opportunity for easy simultaneous local delivery of both therapies.40,41 
Limitations 
The present study has several limitations. Firstly, one of the six horses studied had 
no butorphanol detected in synovial fluid at any time point. Review of perfusion 
technique, perfusion recordings and serum values did not reveal a clear cause for this 
perfusion failure. The unfortunate loss of the data from this horse contributed to the 
limited conclusions that could be drawn from the study. A second limitation was that the 
horses used were clinically normal, limiting the direct translation of findings to diseased 
or surgical patients. It has been reported that drug delivery and opioid receptor activity is 
altered in septic, traumatized or otherwise abnormal tissues, which may result in higher 
drug concentrations and efficacy following IVRLP.14,41,44,75 Additionally, nociceptive 
thresholds and responses to analgesics may be markedly different in healthy horses 
versus those with a painful limb condition.55 Future studies should be pursued to tease 
apart the implications of tissue damage on the therapeutic efficacy of analgesic IVRLP. 
The ultimate limitation of this study was the small sample size, which limited the power 
of the study to make specific comparisons between MNTs of control and treated limbs, as 
well as with respect to site of limb stimulation and specific intra-synovial concentrations 
that resulted in effective analgesia. The study was designed primarily as a proof-of-
concept project to lay the groundwork for objective assessment of analgesic IVRLP 
efficacy and, as such, a small sample size was used. Two pilot horses were used to test 
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the planned procedure prior to the present project and the concentrations achieved in 
these horses were much less variable, suggesting the planned six horses would be 
sufficient. As the sampling was performed differently in these horses, this data was not 
included in the main study due to a desire for consistency. Unfortunately, due to the loss 
of one set of data and the variability in the synovial concentrations achieved, the sample 
size was ultimately insufficient. Given the expected degree of variability and the 
possibility of perfusion failures, future investigations with a larger sample size may allow 
for stronger statistical analyses and conclusions regarding the use of butorphanol IVRLP.  
Conclusions 
The present study is a useful addition to the evaluation of opioids for use as a 
regional analgesic therapy. The procedure appears, subjectively, to be well tolerated both 
locally and systemically at the butorphanol dosage used. The MNT data provides the first 
step towards evaluating the analgesia provided by an opioid IVRLP and further MNT 
research should be pursued to determine what synovial and tissue concentrations of 
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